



Press Release - July 2022

LoValTech wins the 24th edition of the i-Lab Innovation Competition

We are very happy to announce that **LoValTech** is the winner of the 24th i-Lab competition, a prize which was awarded on July 4, in the presence of the Minister of Higher Education, Research and Innovation, Sylvie Retailleau.

Organized by the MESRI and operated by BPI France, the i-Lab Innovation Competition funds each year the **best research and development projects** operated by technology companies less than two years old.

Selection criteria:

- ✓ Innovative nature of the technology and established proof of concept
- ✓ Economic viability of the project
- ✓ Significant potential for development and value creation, including internationally
- ✓ The candidate's motivation, availability and ability to create and develop a business, lead a team and build partnerships
- ✓ Ability of the candidate to get involved in the project
- ✓ Quality and complementarity of the team
- ✓ Mastery of intellectual property and third-party rights (in particular freedom of operation)

In addition, the impacts of the project in terms of sustainable development and societal benefits are taken into account

This prize is naturally very important for us in terms of recognition of the quality of our project, with the State, the scientific community and the world of finance.

It will also allow us to take charge of part of the toxicity study of our vaccine development plan thanks to the financial support of 375 000 € granted by the Prime Minister.

LoValTech is a startup created in January 2022 to take over from the academic research of the University of Tours and INRAE, for the development of new generation vaccines, subunits and in nasal administration, capable of to protect all populations against infectious diseases not/poorly protected by current vaccines.

The first vaccine due to enter the clinical phase in the middle of next year is a vaccine against **Covid-19** which will have 3 critical innovative benefits:

- 1- Its ability to stop the transmission of the virus and therefore its contagiousness
- 2- Its activity on the different variants
- 3- Its conservation at a positive temperature allowing simplified logistics and access to vaccination for emerging countries

Naturally, the non-invasive side of the "nasal spray" will provide an additional benefit.

Contact: patrick.barillot@lovaltechnology.com

Website: <https://lovaltechnology.com>

We would also like to congratulate our Center Val de Loire co-winners, Fabien Berger and Jérôme Barbou from **Fractal Energy**.

With our thanks to MESRI and BPI France for this great initiative!

And big thanks to the platform **PRIMMO** (CHRO) for their precious support.



Patrick Barillot, CEO of LoValTech



LoValTech & Fractal Energy

